Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials

R Shameem, MS Hamid, S Wu - Anticancer Research, 2015 - ar.iiarjournals.org
Background: Everolimus, an inhibitor of mammalian target of rapamycin (mTOR) used for the
treatment of various solid tumors, is associated with anemia, which can lead to morbidity and …

Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis

T Funakoshi, A Latif, MD Galsky - Critical Reviews in Oncology/Hematology, 2013 - Elsevier
We performed a systematic review and meta-analysis of hematologic toxicities associated
with everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor. Eligible studies …

Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis

J Xu, D Tian - Current medical research and opinion, 2014 - Taylor & Francis
Background: Mammalian target of rapamycin (mTOR) inhibitors, temsirolimus and
everolimus, are currently approved for the treatment of several malignancies. Hematological …

Treatment-related mortality with everolimus in cancer patients

R Wesolowski, M Abdel-Rasoul, M Lustberg… - The …, 2014 - academic.oup.com
Introduction. The overall incidence and odds of fatal adverse events (FAEs) after exposure to
everolimus are not well defined. We performed a comprehensive meta-analysis of published …

The risk for anemia with targeted therapies for solid tumors

S Barni, M Cabiddu, P Guarneri, V Lonati… - The oncologist, 2012 - academic.oup.com
Background. Anemia is a common manifestation in patients with cancer. Little is known
about the frequency of and risk for anemia with targeted therapies used to treat solid tumors …

Discontinuation of everolimus due to unrelated adverse events in cancer patients.

SC Rogers, CA Garcia, S Wu - 2016 - ascopubs.org
e14020 Background: The mTOR (mammalian target of rapamycin) inhibitor everolimus, a
targeted agent used widely in cancer patients, is often discontinued due to serious adverse …

[HTML][HTML] Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis

WX Qi, YJ Huang, Y Yao, Z Shen, DL Min - PloS one, 2013 - journals.plos.org
Background Two novel mammalian targets of rapamycin (mTOR) inhibitors everolimus and
temsirolimus are now approved by regulatory agencies and have been widely investigated …

Everolimus-induced hematologic changes in patients with metastatic breast cancer

A Chen, L Chen, A Al-Qaisi, E Romond, M Awasthi… - Clinical Breast …, 2015 - Elsevier
Background Everolimus, which inhibits the mammalian target of rapamycin (mTOR), is
increasingly used in breast cancer and familiarity with its full range of toxicity is critical for …

Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis

O Abdel-Rahman, M Fouad - Future Oncology, 2015 - Future Medicine
Background: We performed a systematic review and meta-analysis of fatigue, hepatic and
metabolic toxicities associated with everolimus intake in patients with solid tumors. Methods …

Risk of gastrointestinal and hepatic toxicities in patients with advanced breast cancer treated with everolimus: A meta-analysis of phase 3 randomized controlled trials.

S Swarup, KZ Thein, A Sultan, S Khan, C Jones… - 2018 - ascopubs.org
e22215 Background: The introduction of everolimus (E), an mTOR inhibitor, was shown to
improve clinical benefit in endocrine and trastuzumab resistant advanced breast cancer by …